Creative Planning Cuts Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Creative Planning trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 5.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,446 shares of the company’s stock after selling 2,731 shares during the period. Creative Planning’s holdings in Elanco Animal Health were worth $726,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. increased its stake in Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after purchasing an additional 1,361 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in Elanco Animal Health in the third quarter valued at approximately $29,000. nVerses Capital LLC purchased a new position in Elanco Animal Health in the second quarter valued at approximately $32,000. ORG Partners LLC purchased a new position in shares of Elanco Animal Health during the second quarter worth approximately $31,000. Finally, Quarry LP purchased a new position in shares of Elanco Animal Health during the second quarter worth approximately $40,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Jeffrey N. Simmons purchased 100,000 shares of the stock in a transaction dated Monday, August 12th. The stock was acquired at an average cost of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The trade was a 200.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. This trade represents a 200.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Harrington purchased 3,500 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research reports. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays lowered their target price on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, October 28th. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.00.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $12.60 on Monday. The firm has a market capitalization of $6.23 billion, a P/E ratio of -4.94, a P/E/G ratio of 1.32 and a beta of 1.41. Elanco Animal Health Incorporated has a 1-year low of $8.75 and a 1-year high of $18.80. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The business’s 50-day simple moving average is $14.11 and its 200-day simple moving average is $14.73.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.18 EPS. Equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.